The global endobronchial ultrasound (EBUS) biopsy market is on a trajectory of consistent growth, driven by a growing preference for minimally invasive diagnostic procedures, increasing incidence of lung cancer, and advancements in imaging and bronchoscopy technology. Valued at USD 733.19 million in 2024, the market is projected to expand at a compound annual growth rate (CAGR) of 4.6% between 2025 and 2034. This growth highlights the evolving landscape of pulmonary diagnostics and the critical role of EBUS biopsy in enabling accurate, safe, and early diagnosis of lung-related conditions.

Market Overview

Endobronchial ultrasound biopsy is a minimally invasive procedure that allows physicians to visualize and sample lesions or lymph nodes in the chest using a bronchoscope equipped with ultrasound. EBUS has emerged as an essential tool in the diagnosis and staging of lung cancer, as well as in evaluating other thoracic diseases such as tuberculosis and sarcoidosis. Its precision, safety profile, and capability to reduce the need for more invasive surgical procedures have significantly contributed to its adoption across healthcare settings.

The increasing prevalence of respiratory diseases, particularly non-small cell lung cancer (NSCLC), has spurred the demand for diagnostic technologies like EBUS. Moreover, ongoing improvements in needle design, imaging clarity, and real-time guidance have further enhanced its utility, making it a preferred choice among pulmonologists and thoracic surgeons.

Key Market Growth Drivers

Rising incidence of lung cancer and respiratory diseases

Lung cancer remains one of the leading causes of cancer-related deaths worldwide. According to the World Health Organization (WHO), lung cancer accounted for approximately 2.2 million new cases and 1.8 million deaths globally in 2023. Early detection plays a critical role in improving patient outcomes, and EBUS biopsy offers an efficient and safe method for early-stage diagnosis and accurate lymph node staging.

Increasing adoption of minimally invasive procedures

Patients and clinicians alike are shifting toward procedures that offer minimal invasiveness, reduced recovery time, and lower risk of complications. EBUS-guided transbronchial needle aspiration (TBNA) fulfills all these criteria, thereby gaining preference over conventional surgical biopsies. Hospitals and diagnostic centers are investing in advanced EBUS systems to improve diagnostic efficiency and enhance patient experience.

Technological advancements in ultrasound and bronchoscopy

The market is also benefitting from rapid advancements in imaging technology, endoscope design, and biopsy tools. Enhanced ultrasound resolution, integration of elastography, and navigation bronchoscopy are pushing the boundaries of diagnostic accuracy. These innovations have increased the clinical utility of EBUS across different diagnostic applications beyond cancer, including infection and inflammatory disease assessment.

Rising healthcare expenditure and awareness

Improved healthcare infrastructure in emerging economies and rising healthcare spending are contributing to greater access to advanced diagnostic modalities. Simultaneously, growing awareness among patients and healthcare providers about the benefits of early cancer screening has led to higher adoption rates of EBUS procedures.

Market Challenges

High cost of equipment and procedures

One of the primary challenges facing the endobronchial ultrasound biopsy market is the high capital investment required for acquiring EBUS systems. The cost of installation, maintenance, and training can be significant, especially for small- and mid-sized healthcare facilities in developing regions. This limits widespread adoption and creates disparities in access to advanced diagnostics.

Limited skilled professionals

Although the procedure is minimally invasive, it demands a high degree of technical skill and expertise. The shortage of trained pulmonologists and bronchoscopists capable of performing EBUS-guided biopsies, particularly in low-resource settings, can hamper the market’s growth potential.

Regulatory and reimbursement hurdles